Scott Alexander argues that Plan A's proposed AI chip regulations are not a dystopian surveillance state, but rather comparable to existing regulations on controlled substances, and that most feared dystopian outcomes already exist in current banking and AI chat monitoring.

Scott Alexander examines the surprisingly broad effects of GLP-1 drugs like Ozempic, exploring their mechanisms and speculating on why they seem to impact so many different conditions.

Scott responds to various comments on his article about supplement labeling, addressing concerns about the industry and providing additional context and analysis.

Scott Alexander proposes using high-dose oral progesterone as a potential low-cost alternative to Zulresso for treating postpartum depression, based on pharmacological research.

Scott Alexander argues that doctors should prescribe fluvoxamine for COVID-19 despite FDA inaction, urging them to overcome discomfort with off-label use when evidence supports it.

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options.

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies.